Merck KGaA has another stab at multiple sclerosis, gaining rights to Peptimmune PI-2301 program
German drug major Merck KGaA (MRK: DE) is taking another look at the multiple sclerosis market, where it is already a leader with its Rebif (interferon beta-1qa), acquiring worldwide exclusive rights to PI-2301, an experimental drug for multiple sclerosis, previously developed by privately-held US biotech Peptimmune. PI-2301 has completed Phase Ib in multiple sclerosis and is ready to initiate Phase II clinical trials.
Merck suffered a disappointment in its attempts to develop an oral MS drug, Movectro (cladribine), finally deciding to drop the program and leaving the tablet sector clear for Swiss drug major Novartis’ Gilenya (fingolimod), which gained regulatory clearance last year (The Pharma Letter June 23). The advent of oral MS treatments is expected to expand the already $10 billion a year MS market to some $15 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze